VIKAS MANGEWALA: Open Payments
NPI 1750641668 · FAIRFAX, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,836 in 72 payments from 18 companies in 2025. Trend: 2023 $1,138 · 2024 $1,703 · 2025 $1,836
Food & beverage: $1,836
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 9 | $234 |
| Janssen Pharmaceuticals, Inc | 4 | $222 |
| Vanda Pharmaceuticals Inc. | 5 | $167 |
| Otsuka America Pharmaceutical, Inc. | 7 | $141 |
| Corium, LLC | 6 | $114 |
| Neurocrine BioSciences, Inc. | 4 | $108 |
| Collegium Pharmaceutical, Inc. | 5 | $104 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $99 |
| ABBVIE INC. | 4 | $97 |
| Bausch Health US, LLC | 4 | $93 |
Products named: UZEDY, SPRAVATO, REXULTI, FANAPT, Azstarys, INGREZZA, Jornay PM, CAPLYTA.
Industry payments across VA — which companies pay providers there.
